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The Brugada syndrome (BrS) is characterized by coved-type ST-segment elevation in
the right precordial leads on the electrocardiogram (ECG) and increased risk of sudden
cardiac death (SCD). While it is an inheritable disease, determining the true prevalence
is a challenge, since patients may report no known family history of the syndrome,
present with a normal spontaneous ECG pattern at the time of examination, and test
negative for all known BrS-causative genes. In fact, SCD is often the first indication
that a person is affected by the syndrome. Men are more likely to be symptomatic
than women. Abnormal, low-voltage, fractionated electrograms have been found in the
epicardium of the right ventricular outflow tract (RVOT). Ablation of this area abolishes
the abnormal electrograms and helps to prevent arrhythmic recurrences. BrS patients
are more likely to experience ventricular tachycardia/fibrillation (VT/VF) during fever or
during an increase in vagal tone. Isoproterenol helps to reverse the ECG BrS phenotype.
In this review, we discuss roles of calcium in various conditions that are relevant to BrS,
such as changes in temperature, heart rate, and vagal tone, and the effects of gender
and isoproterenol on calcium handling. Studies are warranted to further investigate these
mechanisms in models of BrS.
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INTRODUCTION
The Brugada syndrome (BrS) is an inherited disease characterized by coved-type ST-segment
elevation in the right precordial leads on the electrocardiogram (ECG) and increased risk of
sudden cardiac death (SCD) (Brugada and Brugada, 1992). BrS often presents in seemingly
otherwise healthy young adults, although it has been found in patients from 2 days to 84 years
old (Antzelevitch et al., 2005), and sometimes SCD (or aborted SCD) is the first indication that the
patient is affected by BrS. BrS can be inherited as an autosomal dominant trait with incomplete
penetrance (Chen et al., 1998; Nademanee et al., 2011; Lieve and Wilde, 2015), although in a recent
study observing 135 consecutive patients with BrS, most patients did not report a family history of
sudden death (Pappone et al., 2017). It is more often found in males than in females (Nademanee
et al., 1997; Pappone et al., 2017) and is most prevalent in southeast Asia (Nademanee et al., 1997;
Miyasaka et al., 2001; Antzelevitch et al., 2005; Napolitano and Priori, 2006; Sidik et al., 2009;
Lieve and Wilde, 2015), where it is the leading cause of natural death in males under 50 years
old (Brugada et al., 2005). Abnormal, low-voltage, fractionated electrograms have been found
in the epicardium of the right ventricular outflow tract (RVOT). Ablation of this area abolishes
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the abnormal electrograms and helps to prevent arrhythmic
recurrences (Pappone et al., 2017). This area, the arrhythmogenic
substrate (AS), increases in size when ajmaline is administered,
thus revealing the full extent of the area requiring ablation
(Pappone et al., 2017). BrS patients are more likely to
experience ventricular tachycardia/fibrillation (VT/VF)
during fever (Martins et al., 2014) or during an increase in
vagal tone (Nakazawa et al., 2003). Intravenous isoproterenol
administration is beneficial for BrS patients (Kasanuki et al.,
1997; Yan and Antzelevitch, 1999; Maury et al., 2004; Watanabe
et al., 2006; Jongman et al., 2007). Acute myocardial ischemia of
the RVOT occasionally results in a Brugada-like ECG pattern,
although this is categorized as a Brugada phenocopy, rather than
true BrS (Nakamura et al., 2017).
There have been excellent reviews on the pathophysiology
of BrS and the proposed responsible mechanisms (Hoogendijk
et al., 2010; Sieira et al., 2016). In this focused review, we discuss
the role of calcium and how calcium mishandling should be
investigated in BrS, especially in relation to factors that trigger
arrhythmic events, such as changes in temperature, heart rate,
and vagal tone. The role of gender and the beneficial effects
of isoproterenol administration are also addressed. Studies are
warranted to further investigate these mechanisms in models of
BrS. We hope that this review stimulates debate about the role of
calcium in BrS and inspires future research.
BRUGADA SYNDROME: CALCIUM AND
CONTRACTION
The diagnosis of BrS is based upon the presence of a specific
ECG finding, namely a coved ST-segment elevation followed
by a negative T wave in the anterior right precordial leads
(Brugada et al., 1993; Curcio et al., 2017). An elevated ST-segment
can manifest in patients with a variety of genetic mutations,
ranging from mutated ion channel proteins (Curcio et al., 2017)
to mutated sarcomeric proteins (Campuzano et al., 2015; Di
Resta et al., 2015; Mango et al., 2016; Monasky et al., 2017a;
Song et al., 2017; Pappone, 2018), but often mutations are
not detected (Curcio et al., 2017). There are several excellent
reviews that discuss the various theories for the mechanism
of BrS (Antzelevitch et al., 2003, 2005, 2016b; Antzelevitch,
2005; Meregalli et al., 2005; Antzelevitch and Burashnikov,
2011; Nademanee et al., 2015; Antzelevitch and Patocskai, 2016;
Havakuk and Viskin, 2016). However, whether the underlying
mechanism is due to conductance abnormalities arising from
increased fibrosis or connexin defects or a channelopathy or
sarcomeropathy, ultimately an elevated ST segment and negative
T wave are produced. The ST segment and T wave correspond
with phases 2 and 3 of the action potential, respectively
(Paulev and Zubieta-Calleja, 1999), which correspond with
intracellular calcium rise and fall, respectively (Santana et al.,
2010). Antzelevitch (2002, 2006) and Antzelevitch et al. (2016a)
have suggested a mechanism in BrS involving calcium depletion
in cells as a consequence of reduced calcium channel current
resulting from loss of the action potential. This could lead to
wall motion abnormalities, particularly in the RVOT, dilation
of the RVOT region, and reduced ejection fraction (EF)
(Antzelevitch et al., 2016a). Moreover, sodium channel loss-
of-function mutations, which occur in about 15–30% of BrS
cases (Kapplinger et al., 2010), impair the function of NCX,
leading to alterations in intracellular calcium (Ottolia et al.,
2013). This is relevant during both systole and diastole. If there
exists a loss-of-function of the sodium channels, not enough
sodium will enter the cell during phase 0 to exit the cell during
phase 2, which is necessary to drive the NCX to bring calcium
into the cell (Figure 1). Calcium that normally enters the cell
during phase 2 via NCX triggers additional sarco(endo)plasmic
reticulum (SR) calcium release via activation of the ryanodine
receptors. Therefore, reduced calcium influx via NCX may lead
to reduced SR calcium release. During diastole, reductions in
intracellular calcium may result in a loss of calcium from the cell
as the SR is unable to effectively compete with NCX for calcium
uptake. A reduction in SR calcium store would ultimately lead
to a reduction in contractility. Therefore, a loss-of-function of
the sodium channel, which occurs in many BrS patients, would
impair physiological calcium handling, although to what extent is
uncertain. Abnormalities in calcium signaling (increase/decrease
in calcium transient amplitude or alterations in kinetics of
calcium transport) result in changes in the amount of calcium
available to bind to troponin C of the myofilaments to induce or
sustain contraction. Therefore, disruptions to the action potential
can lead to calcium mishandling and disrupted excitation-
contraction coupling. Thus, BrS patients are at higher risk of
experiencing contractile dysfunction than people without BrS.
Reduced contractility in BrS is supported by several studies.
Catalano et al. (2009) described RVOT diameter, area, and
volume to be similar in BrS and control patients, but RVOT EF
was decreased in BrS patients due to an increased end systolic
volume (ESV). Tukkie et al. (2004) demonstrated that RV ejection
time shortens as the ECG BrS pattern develops during flecainide
challenge, suggesting reduced calcium influx. Rudic et al. (2016b)
reported significantly lower RVEF, as well as a trend toward
lower LVEF, in BrS patients compared with healthy controls.
Papavassiliu et al. (2010) reported patients with a spontaneous
type 1 BrS ECG with significantly lower RVEF and ESV compared
to controls. van Hoorn et al. (2012) described patients with the
SCN5A sodium channel mutation having significantly larger end
diastolic volume (EDV) and ESV in the RV and LV compared
to patients without the SCN5A mutation or volunteers. Thus,
contractility is reduced in BrS, which, accompanied by altered ST
segment and T wave ECG recordings, suggests altered calcium
handling during excitation-contraction coupling. Studies are
warranted to further investigate calcium signaling in BrS.
In addition to contractile dysfunction, BrS is associated
with structural abnormalities. Miyazaki et al. (1996) named the
presence of right bundle branch block, ST segment elevation,
and ventricular tachyarrhythmias “Brugada syndrome.” This
was after Brugada and Brugada (1992) had described right
bundle branch block, normal QT interval, and persistent ST
segment elevation in precordial leads V1 to V2–V3 in the
absence of echocardiographic or histologic abnormalities as
being a distinct syndrome different from idiopathic ventricular
fibrillation. However, before that, in Martini et al. (1989) had
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FIGURE 1 | Physiological calcium handing (A–E) and hypothesis for calcium handing with loss-of-function of sodium channel (F–J) during cardiac excitation and
relaxation. NCX: Na+/Ca2+ exchanger-1; NaV1.5: sodium channel; LTCC: L-type calcium channel; RyR: Ryanodine receptor; SERCA: sarco(endo)plasmic reticulum
Ca2+-ATPase 2a; PLN: phospholamban.
described six patients resuscitated from ventricular fibrillation.
An upsloping ST-T segment elevation (“early repolarization”)
was observed in three patients in V1, V2. Stimulation of the
RVOT during electrophysiological study triggered ventricular
fibrillation. Although structural heart disease had been initially
excluded, abnormalities, predominantly of the right ventricle,
were realized after a more in-depth assessment. Fibrosis was
detected in three of the patients. Half of the patients were
at rest when the ventricular fibrillation occurred, four out of
six had no preexisting symptoms, and five out of six had no
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documented arrhythmias. The group concluded that electrical
heart disease may often be associated with a pathological
substrate predominantly in the right ventricle, and that greater
attention should be given to ECG patterns of right bundle
branch block, early repolarization (ST segment elevation),
inverted T waves, and late QRS potentials (Martini et al.,
1989) [also see letter arguing for the existence of structural
abnormalities (Martini et al., 1993)]. Nevertheless, a great amount
of literature over the following decades referred to BrS as
an electrical disease without structural abnormalities. More
recently, the dogma surrounding this issue has reversed to
recognize that in fact structural abnormalities exist. BrS is now
accepted to be associated with epicardial surface and interstitial
fibrosis (Coronel et al., 2005; Nademanee et al., 2015), reduced
gap junction expression, and increased collagen (Nademanee
et al., 2015). Right ventricular histological samples from BrS
patients have exhibited myocarditis, cardiomyopathic changes,
or myocardial fatty infiltration typical of arrhythmogenic right
ventricular cardiomyopathy (ARVC) (Frustaci et al., 2005). These
studies support earlier ones, such as the one by Corrado et al.
(2001) which aimed to assess the prevalence of right precordial
ST-segment elevation in young sudden death victims, and found
that this ECG pattern was strongly correlated with RV structural
abnormalities consistent with ARVC involving predominantly
the RV anterior wall. While little is known about calcium
handling in BrS, structural cardiomyopathies such as ARVC are
associated with significant pathological calcium handing (for
an excellent review, see van Opbergen et al., 2017). In short,
the field now recognizes that BrS is associated with structural
abnormalities. Therefore, what is already known about calcium
mishandling in these pathologies (i.e., ARVC, myocarditis, etc.)
could be applied as a starting point to hypothesize about calcium
mishandling in BrS.
THE GENETICS OF BRUGADA
SYNDROME: ION CHANNEL,
SARCOMERIC, AND MITOCHONDRIAL
MUTATIONS
Brugada syndrome cases are consistently familial: BrS exhibits an
autosomal dominant pattern of inheritance with equal genetic
transmission to both genders. Recent technical improvements
have changed BrS molecular diagnostic testing capabilities. Next
generation sequencing allows a cost-effective genetic analysis.
Using this method, nearly 300 pathogenic variants in 22 different
genes have been published to date. The genes today associated
with BrS can codify for sodium channels, sodium channel
regulators, sarcolemma associated proteins, potassium channels,
calcium channels, trafficking regulators, and signaling proteins
(Kapplinger et al., 2010; Di Resta et al., 2015).
The three most common types of genetic variations found
in BrS patients are missense, nonsense, and splicing mutations.
Excellent reviews have been written on this subject (Kapplinger
et al., 2010; Wilde and Amin, 2018). A missense mutation is a
change in one DNA base pair that results in the substitution
of one amino acid for another in the protein codified by a
certain gene (Skinner and Love, 2010). In medical literature, it
is well known that missense mutations are found in almost two
thirds of BrS patients who are found to have a mutation during
genetic screening (Kapplinger et al., 2010). Missense mutations
in SCN5A are an important molecular cause of BrS (Kapplinger
et al., 2010). For example, missense heterozygous mutations like
c.1066G> A (p.Asp356Asn) or c.4222G> A (p.Gly1408Arg) are
observed in BrS patients. Loss-of-function missense mutations
have been described in CACNA1C (A39V and G490R) and
CACNB2 (S481L), which encode the alpha1- and beta2b-subunits
of the L-type calcium channel (Antzelevitch et al., 2007). These
calcium channel mutations have been identified in BrS patients
who also exhibit shorter-than-normal QT intervals (Antzelevitch
et al., 2007).
In a nonsense mutation, the altered DNA sequence
prematurely signals the cell to stop producing a protein.
This type of mutation results in a shortened protein that may
function improperly or not at all. A subgroup of BrS patients
harbor a heterozygous nonsense mutation, most commonly
in the SCN5A gene (Teng et al., 2017). Two examples of
this kind of mutation are c.4867C > T (p.Arg1623Ter) and
c.5435C > A (p.Ser1812Ter), both associated with serious
functional alterations in the NaV1.5 protein, codified by the
SCN5A gene.
Splicing is the editing of precursor messenger RNA into
mature messenger RNA, removing non-coding regions (called
“introns”) and joining together all coding regions (Qin et al.,
2018). Theoretically, every kind of mutation can affect the
splicing process, for example with exon skipping, intron
retention, or cryptic splice site activation (Peccarelli and Kebaara,
2014). Fukuyama et al. (2014) reported an important example of
this in 2014. They described a missense heterozygous mutation
in the CACNA1C gene (c.1896G > A, p. Arg632Arg) causing an
exon skipping in mRNA.
A less common type of mutation found in BrS patients is
the frameshift mutation, which occurs when the addition or loss
of DNA bases changes a gene’s reading frame. A reading frame
consists of groups of three bases, each coding for one amino
acid. A frameshift mutation shifts the grouping of these bases
and changes the code for amino acids. The resulting protein is
usually nonfunctional. A clear example of this in BrS can be found
in the heterozygous mutation D1816VfsX7 in the SCN5A gene
(Dolz-Gaiton et al., 2013). Insertions, deletions, and duplications
can all be frameshift mutations and have been described in BrS
(Mobius-Winkler et al., 2011). An insertion changes the number
of DNA bases in a gene by adding a piece of DNA. As a result, the
protein made by the gene may not function properly. A deletion
changes the number of DNA bases by removing a piece of DNA.
Small deletions may remove one or a few base pairs within a
gene, while larger deletions can remove an entire gene or several
neighboring genes. The deleted DNA may alter the function
of the resulting protein(s). A duplication consists of a piece of
DNA that is abnormally copied one or more times. In medical
literature, large deletions involving both the SCN5A and SCN10A
genes are described as an emerging cause of BrS (Sonoda et al.,
2018).
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In one report, a Brugada phenotype was described as X-linked,
likely caused by a mutation in the KCNE5 gene (Ohno et al.,
2011). It is sufficient to harbor a single copy mutation in a
diseased gene to be affected by BrS, with a 50% recurrence risk
if molecularly confirmed. The most commonly mutated gene
in BrS is SCN5A (Di Resta et al., 2015; Sieira et al., 2016;
Curcio et al., 2017), which encodes for the alpha subunit of
the cardiac sodium channel (Di Resta et al., 2015), although
a mutation in one of several genes can be causative of BrS
(Table 1). Pathogenic variants in SCN5A are associated with
a functional impairment, not only in the sodium channel
(Calloe et al., 2013), but also in the whole heart (van Hoorn
et al., 2012). Mutations in the SCN5A gene have been found
responsible for ARVC, atrial standstill type 1, atrial fibrillation,
left ventricular noncompaction, dilated cardiomyopathy, Long
QT syndrome type 3, sick sinus syndrome type 2, idiopathic
ventricular fibrillation, and heart block type 1A (Gosselin-
Badaroudine et al., 2014; Zaklyazminskaya and Dzemeshkevich,
2016). Calcium channel mutations in CACNA1C, CACNB2b,
and CACNA2D1 are all associated with loss-of-function of the
channel and have been extensively reviewed previously, including
the loss-of-function mutations that occur in these genes in Short
QT Syndrome and Early Repolarization Syndrome (Betzenhauser
et al., 2015).
Understanding the effects of each mutation is quite complex,
especially when an individual BrS patient harbors pathogenic
variants in two or more genes. In addition, pathogenic variants
in SCN1B, SCN2B, and SCN3B genes can act as disease modifiers
rather than as a single molecular cause of BrS (Watanabe et al.,
2008; Riuro et al., 2013). Furthermore, BrS can coexist with
other phenotypes within the same individual, such as Long QT
syndrome type 3 or Lev-Lenègre disease (Meregalli et al., 2005).
It is very common that family members with the same mutation
can have different phenotypes between members of that family
[left ventricular noncompaction or BrS (Pappone, 2018); BrS in
males but Lev-Lenègre disease in females (Kyndt et al., 2001;
Meregalli et al., 2005)]. Future studies are warranted to better
understand how specific mutations result in different phenotypes
between individuals. In particular, it is already unclear how
females with BrS can be asymptomatic more frequently than
TABLE 1 | Mutated genes used to molecularly confirm BrS.
Genes Patients Reference
CACNA1C, CACNB2 82 Antzelevitch et al., 2007
CACNA1C, CACNA2D1,
CACNB2
162 Burashnikov et al., 2010
SCN5A 2111 Kapplinger et al., 2010
KCNJ8 204 Barajas-Martinez et al., 2012
ABCC9 150 Hu et al., 2014
AKAP9, ANK2, KCNJ2,
CASQ1, RYR2
45 Allegue et al., 2015
KCNH2, ANK2, SCN5A, RYR2 16 Farrugia et al., 2015
SCN5A 1 Chen et al., 2016
CACNA1C 1 Bai et al., 2017
SCN1B 23 Gray et al., 2018
males and how important genetic modifiers can explain the
incomplete penetrance and clinical variability of BrS familial
cases. One study examining the role of mitochondrial DNA
used PCR-SSCP analysis to describe four recurrent mutations
in mitochondrial tRNA genes associated with BrS for the first
time (Tafti et al., 2018). This suggested that mitochondrial DNA
may lead to functional deficiencies in the translational process of
myocardial proteins (i.e., a frameshift mutation). This can lead to
nonfunctioning proteins important in BrS.
Although BrS has commonly been described as a
channelopathy, several studies have now identified sarcomeric
mutations with the syndrome (Ishikawa et al., 2012; Campuzano
et al., 2015; Di Resta et al., 2015; Mango et al., 2016; Monasky
et al., 2017a; Song et al., 2017; Pappone, 2018), suggesting
BrS may originate as a sarcomeropathy. Like many forms of
arrhythmia and cardiomyopathy, BrS can originate from a
variety of mechanisms. Thus, there may be no one underlying
mechanism for BrS, but likely there are several mechanisms that
ultimately converge into one common pathway that results in
a particular recognizable phenotype. Thus, the question when
sarcomeric mutations are detected becomes: could sarcomeric
mutations result in a BrS phenotype?
While sarcolemmal calcium transport proteins clearly play
a vital role in calcium transport and thus activation of the
myofilaments, it has long been established that contractile force
and relaxation are not merely regulated by passive binding
and unbinding of calcium to the myofilaments, but that the
myofilaments independently regulate this process (Monasky
et al., 2008a, 2017b). This can occur, for example, through
genetic mutations (Baudenbacher et al., 2008; Yar et al., 2013;
Alves et al., 2014; van der Velden et al., 2015) or post-
translational modifications (Varian et al., 2009; Monasky et al.,
2010, 2013; Lovelock et al., 2012) of the myofilaments that alter
myofilament calcium sensitivity (MCS). In pulmonary artery
banded rabbits, mechanical strain placed on the myofilaments
feeds back to regulate calcium signaling by decreasing expression
of the SR Ca2+-ATPase (SERCA) 2a and increasing expression
of the Na+/Ca2+ exchanger-1 (NCX) (Gupta et al., 2009).
Mutated troponin T leading to increased MCS in mice results in
arrhythmia susceptibility (Baudenbacher et al., 2008; Yar et al.,
2014). It has been suggested that calcium sensitization causes a
substrate for reentrant activation (Huke and Knollmann, 2010).
The role of increased MCS on arrhythmia susceptibility has been
extensively reviewed elsewhere (Huke and Knollmann, 2010).
Future studies are warranted to understand MCS and its role in
arrhythmia susceptibility in BrS. This is particularly interesting
in individuals with overlap diseases, such as hypertrophic
cardiomyopathy, dilated cardiomyopathy, or ARVC in addition
to BrS (Gray et al., 2014; Steiner et al., 2014; Mango et al.,
2016; Monasky et al., 2017a), or families in which different
family members with the same sarcomeric mutation exhibit
diverse phenotypes, including BrS and another cardiomyopathy
(Pappone, 2018).
Genetic Models
Considering up to 30% of BrS cases have been mainly associated
with a genetic mutation in the SCN5A gene, (London et al., 2007)
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the creation of animal models carrying these mutations is very
useful for the characterization of the pathophysiology of BrS. Park
et al. (2015) have described a pig model with a SCN5A nonsense
mutation (E558X) previously found in a child with BrS. This
model exhibited slowed conduction and increased susceptibility
to ventricular arrhythmias, and presents a promising model
for future BrS studies. Indeed, the creation of a mutant pig
model, which has a more similar cardiac structure and function
to humans than smaller animal models, is extremely useful to
understanding BrS. The action potential and calcium handling
are known to greatly differ between species, thus making a
larger animal model preferable to understanding BrS in humans
(Milani-Nejad and Janssen, 2014).
Murine models have also been used. Although the action
potentials and calcium handling differ greatly between mice
and humans, these models can be more quickly and cost-
effectively created, are easier to handle and house, and have
provided a great deal of knowledge. Thus, murine models
are preferred by a number of groups. Indeed, a murine
heterozygous SCN5A+/− model was generated for BrS in vivo
studies (Papadatos et al., 2002). This model has been used by
several groups to mimic BrS, demonstrating how the SCN5A
haploinsufficiency was responsible for the onset of a complex
range of phenotypes, including a 50% reduction of sodium
conductance, a delayed intramyocardial conduction, a sinus
node dysfunction, and ventricular arrhythmogenesis, which are
hallmarks of BrS patients (Zhang et al., 2014; Tse et al., 2017; Kelly
et al., 2018). However, caution must be made when translating
the results of action potential studies in murine models to the
situation in humans, as many differences exist between the
species (Milani-Nejad and Janssen, 2014).
Some kinds of genomic rearrangements, such as deletion
or duplication, in the SCN5A gene can cause BrS as well
(Sonoda et al., 2018). Alternative models must be made for
the remaining ∼70% of patients who do not carry a SCN5A
mutation. Moreover, BrS has been currently associated with
“new” genetic mutations (Antzelevitch and Patocskai, 2016).
Thus, creating informative animal models is a challenge because:
(a) it is unclear which is the main mutation involved in the onset
of the pathology, and (b) these models should develop the same
phenotype, independently from the different genetic alterations.
Therefore, it would be ideal to start with more comprehensive
human genomic studies. Comparative studies between affected
individuals from different races, such as East Asian vs. Caucasian,
could help elucidate which mutations are actually responsible
for the phenotype, since there is a higher prevalence observed
clinically in East Asian countries. Additionally, the impact of
sarcomeropathies in BrS remains an open question.
THE ARRHYTHMOGENIC SUBSTRATE
Several studies have described the AS responsible for
abnormalities seen in the ECG in BrS to be located in
the RVOT (Lambiase et al., 2009; Nademanee et al., 2011;
Sunsaneewitayakul et al., 2012; Cortez-Dias et al., 2014; Rudic
et al., 2016a). Studies in rabbit myocytes suggest this may be
partially explained by a wider range of action potential durations
(APDs) in RVOT myocytes compared to RV myocytes, which
is an important factor in arrhythmogenesis (Liang et al., 2012).
Prolongation of the APD in RVOT myocytes can be caused in
part by higher current density of ICa−L, which normally occurs
in RVOT myocytes (Liang et al., 2012). This suggests that RVOT
myocytes normally rely more heavily on L-type calcium channel
current, which would suggest that the RVOT relies more heavily
on the SR calcium that the increased L-type calcium channel
current would trigger, compared to RV myocytes. Differences
in the embryological origins of RVOT and RV cardiomyocytes
may help explain these differences (Liang et al., 2012), as the
RVOT may have retained embryonic features as it originated
from the more slowly conducting embryonic outflow tract (Rana
et al., 2007; Boukens et al., 2013). The transversal conduction
velocity is further reduced in the RVOT compared to the RV
in healthy myocardium after ajmaline administration (Boukens
et al., 2013). In a mouse model of BrS, with a 1798InsD mutation
in SCN5A, conduction velocity was reduced in both RVOT and
RV compared to wild type, but was more pronounced in the
RVOT, suggesting the continued presence of the embryonic
gene program (Boukens et al., 2013). Demembranated human
embryonic stem cell-derived cardiomyocytes (d-hESC-CMs)
exhibit reduced maximal generated force, increased calcium
sensitivity, faster kinetics of force re-development at submaximal
activation levels, and faster kinetics of the slow relaxation phase
compared to adult human ventricular myofibrils, probably due
to differential sarcomeric protein isoform expression (Iorga
et al., 2017). Future studies could also investigate the distribution
of calcium cycling related genes at the mRNA and/or protein
levels compared to other anatomical positions in the heart.
Further studies are warranted to understand why and how the
AS originates at the RVOT in BrS.
AJMALINE TO DIAGNOSIS AND
RESEARCH BRUGADA SYNDROME
A sodium channel blocking agent, such as ajmaline (Yap et al.,
2009; Dobbels et al., 2016), is used to provoke the type 1 BrS ECG
pattern to affirmatively diagnose the syndrome in patients with
spontaneous type 2, type 3, or normal ECG patterns (Antzelevitch
et al., 2016b; Havakuk and Viskin, 2016; Rudic et al., 2016a).
Together with epicardial mapping, ajmaline challenge can reveal
the extent of the AS (Pappone et al., 2017). Prolonged fragmented
ventricular potentials have been used to define the extent of
the AS in BrS (Pappone et al., 2017). VT/VF is a possible side
effect of ajmaline administration (Conte et al., 2013; Dobbels
et al., 2016). Care must be made to watch a patient’s response
to the ajmaline administration, including using a slow infusion
rate and stopping the administration early in patients whose
ECG changes rapidly (Arnalsteen-Dassonvalle et al., 2010). Thus,
ajmaline aids to uncover and visualize the extent of the AS.
Understanding better the mechanism of ajmaline could lead to
better understanding of the mechanism of BrS. For example,
what are the effects of ajmaline on potassium and calcium
signaling? What post-translational modifications of ion signaling
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proteins and contractile proteins occur as a result of ajmaline
administration? How does ajmaline provoke a type 1 BrS pattern
even in patients negative for sodium channel mutations? It
would be particularly interesting to see the effects of ajmaline
on proteins involved in the β-adrenergic signaling pathway,
since isoproterenol reverses the effects of ajmaline. Thus, further
studies are warranted to better understand the mechanism of
ajmaline.
FEVER AND BRUGADA SYNDROME:
CALCIUM, TEMPERATURE, AND HEART
RATE
Brugada syndrome patients are more likely to experience T wave
abnormalities and VT/VF during a febrile state (Martins et al.,
2014). Normally, hyperthermia is accompanied by an increase
in heart rate (Karjalainen and Viitasalo, 1986). Studies from
healthy rabbit and rat myocardium indicate that an increase
in heart rate alone causes an increase in intracellular calcium
amplitude, an increase in developed force of contraction, and
decreased MCS (Hiranandani et al., 2006; Varian and Janssen,
2007) (Figure 2A). The decrease in MCS allows the myocardium
to relax faster at high heart rates to ensure adequate refilling of
the heart chamber before the next contraction and is countered
by an increase in intracellular calcium, which results in a
net inotropic effect (Varian and Janssen, 2007; Varian et al.,
2009). Experiments in rats demonstrate that an increase in
temperature, however, diminishes this inotropic effect of heart
rate (Hiranandani et al., 2006). In fact, higher temperatures
reduce the force of contraction despite a rise in intracellular
calcium (Hiranandani et al., 2006). This suggests a reduction
in MCS from an increase in temperature alone, which could
be exacerbated at high heart rates, which also independently
reduce MCS. Antzelevitch and colleagues (Antzelevitch, 2002,
2006; Antzelevitch et al., 2016a) have suggested a mechanism
in BrS involving calcium depletion in cells as a consequence
of reduced calcium channel current resulting from loss of the
action potential. If in fact calcium depletion occurs in BrS,
contractile malfunction may become more evident at higher
heart rates when calcium handling proteins are stressed to cycle
calcium more quickly, and the reductions in cytosolic calcium
become more significant (Varian et al., 2009). Cells would have
difficulty drawing the extra calcium from the SR to produce
the increase in intracellular calcium amplitude that is normally
seen at higher heart rates. Additionally, channelopathies, such as
loss-of-function of sodium channels, can prevent physiological
alterations in calcium handling that are normally seen with
changes in temperature or heart rate, since calcium signaling
is dependent on sodium signaling (Figure 2B). Furthermore,
reduced cytosolic calcium could reduce contractility more
noticeably at higher heart rates due to the reduced MCS. It
would be interesting for future studies to investigate calcium
signaling and store in BrS and how this is altered with changes
in temperature and heart rate. It would be particularly interesting
to investigate the mechanisms involved in myocardial relaxation
and intracellular calcium decline, since alterations in T wave
tracings are seen in feverish BrS patients, and T waves correspond
to phase 3 of the action potential (Paulev and Zubieta-Calleja,
1999), when intracellular calcium is being transported out of
the cytosol. Due to the alterations in MCS that occur during
higher temperatures and heart rate and the ability of myofilament
calcium buffering to affect calcium uptake, alterations to the
sarcomeric proteins would also be of interest for future studies.
VAGAL TONE AND RISK OF
ARRHYTHMIAS IN BRUGADA
SYNDROME
The cardiac parasympathetic (vagal) nerves, the sympathetic
nerves, and the pacemaker cells are essentially the factors that
contribute to heart rhythm (Coote and White, 2015). In a review
by Hou et al. (2016) the authors have noted that increased
vagal tone or decreased sympathetic function may worsen
arrhythmogenesis in patients with J-wave syndrome, including
BrS, contrary to most other ventricular tachyarrhythmias. In fact,
several BrS studies suggest an association between an increase in
vagal tone and an increased risk for arrhythmic events (Nakazawa
et al., 2003), which may occur while resting, sleeping (Mizumaki
et al., 2006; Takigawa et al., 2008; Lieve and Wilde, 2015), after
a large meal (Lieve and Wilde, 2015), or while vomiting (Arai
et al., 2004). Parasympathetic stimulation results in an elevated
ST segment, and it has been suggested the mechanism is through
a reduction in ICa−L during the action potential plateau (Litovsky
and Antzelevitch, 1990; Meregalli et al., 2005). Enhanced vagal
tone can also lead to reduced heart rate (Coote and White,
2015; Ponganis et al., 2017). Studies from healthy rat and rabbit
myocardium indicate that a decrease in heart rate, in turn, results
in a decrease in intracellular calcium amplitude, a decrease in
developed force of contraction, and increased MCS (Hiranandani
et al., 2006; Varian and Janssen, 2007). Thus, lower heart rates
are associated with less intracellular calcium, and a reduction of
calcium current is associated with the development of an elevated
ST segment. It would be interesting to study this mechanism
further in models of BrS to understand the level of calcium
present in the cell before parasympathetic stimulation, as well as
the role of calcium during parasympathetic stimulation.
PERCEIVED PREVALENCE, GENETIC
TRANSMISSION, AND HORMONE
REGULATION
Brugada syndrome is more often found in males than in females
(Nademanee et al., 1997; Pappone et al., 2017), despite equal
genetic transmission to both genders (Meregalli et al., 2005).
BrS signs and symptoms can manifest in adulthood in patients
who previously tested ajmaline negative and who had normal
ECGs in childhood, including patients with or without a genetic
mutation associated with BrS (Conte et al., 2014), suggesting
a role for hormones in BrS. In another report, the typical BrS
ECG pattern disappeared in two patients who underwent surgical
castration for prostate cancer, suggesting a role for testosterone
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FIGURE 2 | Physiological response to hyperthermia (A). Hypothesis for mechanism of ECG abnormalities during fever in patients with sodium loss-of-function
mutations (B). References: a (Karjalainen and Viitasalo, 1986); b (Hiranandani et al., 2006); c (Varian and Janssen, 2007); d (Varian et al., 2009); and e (Ottolia et al.,
2013).
(Matsuo et al., 2003). Gender impacts autonomic control of the
cardiovascular system, including vagal modulation and heart
rate, and thus may play an additional role in the mechanisms
discussed earlier in this article (Mann et al., 2012; Pothineni et al.,
2016). Estrogen upregulates L-type calcium channels, and thus
plays a role in calcium handling (Yang et al., 2012), which is
important in BrS as described earlier above. Although contractile
performance and β-adrenergic response has been reported to be
not significantly different between the genders in healthy isolated
rat cardiac trabeculae (Monasky et al., 2008b), there are gender
differences in ion channel and transporter subunit expression
in non-diseased human hearts (Gaborit et al., 2010), suggesting
there could be a role for gender in disease states in which
calcium handling is pathologically altered. Hormone regulation
of cell communication and differences in ion transport are thus
important topics for future research in BrS. Future studies should
investigate how hormone regulation may place men at greater
risk generally, making it easier for them to be diagnosed, and
how gender alters the risk of arrhythmic events during triggering
factors (i.e., fever, decreased vagal tone), making it even easier for
men to be diagnosed.
β-ADRENERGIC RESPONSE,
ISOPROTERENOL USE IN BRUGADA
SYNDROME PATIENTS
Several studies have reported that intravenous isoproterenol
administration reduces ST elevation in leads V1 to V3 and
restores the action potential dome in BrS experimental models
and patients by increasing calcium current (Kasanuki et al., 1997;
Yan and Antzelevitch, 1999; Maury et al., 2004; Watanabe et al.,
2006; Jongman et al., 2007). Jongman et al. (2007) have further
reported a patient who experienced a “clear positive result
on the recurrence of VF” after isoproterenol administration,
while no increase in heart rate was observed, concluding that
the therapeutic mechanism was likely a direct effect on the
myocytes, rather than a beneficial effect from a higher heart
rate. β-adrenergic stimulation by isoproterenol increases SR
calcium content and increases the rate of calcium transient decay
by phosphorylating phospholamban, relieving its inhibition on
SERCA (Wegener et al., 1989; Neumann et al., 1995; Eisner
et al., 2000; Grimm and Brown, 2010). β-adrenergic receptor
stimulation also leads to the phosphorylation of cardiac myosin
binding protein C and troponin I (Neumann et al., 1995;
Grimm and Brown, 2010), which leads to reduced MCS, faster
release of calcium from the myofilaments, and faster relaxation.
Thus, in addition to increasing calcium current, isoproterenol
administration leads to an increased SR calcium content and a
shorter diastole through PKA activation, resetting the cell for
the next activation. Furthermore, PKA activated by β-adrenergic
receptor stimulation leads to an acute time-dependent increase
of sodium current (Abriel, 2007), which would help the cell to
accumulate calcium (Ottolia et al., 2013). Future experiments are
warranted to investigate the calcium handing and SR calcium
store in BrS, as well as the effect of isoproterenol on calcium
handling in these models in the presence of arrhythmogenic
triggering factors. An interesting hypothesis would be that
isoproterenol works by restoring calcium to physiological levels
in BrS. This would be consistent with the finding that β-blockers,
which work to block the β-adrenergic response, are not effective
for BrS patients, as reported by Brugada et al. (1998).
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BRUGADA PHENOCOPY DURING
ISCHEMIA
Brugada phenocopies (BrPs) describe conditions that produce
Brugada-like ECG patterns but are generated by other clinical
or technical factors (Baranchuk et al., 2012; Anselm et al.,
2014; Agrawal et al., 2015). One such BrP occasionally occurs
during acute myocardial ischemia of the RVOT (Nakamura
et al., 2017). Nakamura et al. demonstrated that this type of
BrP predominantly occurs in male patients and that subsequent
development of VT/VF may result (Nakamura et al., 2017).
Interestingly, in the same study, VT/VF was reported in patients
without any obstructive lesion, but arrhythmic events were not
detected when preceded by coronary occlusion or stenosis of
the conus or RV branch, suggesting an effect of preconditioning
(Nakamura et al., 2017). In rats, preconditioning with isoflurane
prevents ischemia/reperfusion-related degradation of RyR and
SERCA (An et al., 2007). Eisner et al. have described a role for
SR calcium in ischemia (Eisner et al., 2000). During ischemia,
decreases in [ATP] hinder SERCA activity and thus calcium
uptake into the SR (Eisner et al., 2000). Despite this, an inhibitory
effect on also the RyR may result in the net increase in the
SR calcium store (Eisner et al., 2000). This decrease in both
release and uptake of calcium from the SR suggests a reduced
role for SR calcium in the activation and relaxation of the
myocardium. Thus, alterations in the cell’s reliance on SR calcium
during ischemia may mimic on clinical exams other situations
in which the cell’s reliance on SR calcium is altered. Since
calcium plays a significant role in ischemia, which can result
in a BrP, it would be interesting to further study the role of
RyR and SERCA activity in BrS. Furthermore, as mentioned
above, it has been suggested that a reduced ICa−L during
the action potential plateau can contribute to an elevated ST
segment during parasympathetic stimulation (Meregalli et al.,
2005). Thus, the role of calcium and how it can contribute to
an elevated ST segment in BrS should be further investigated.
Additionally, the finding that BrP during acute myocardial
ischemia predominantly occurs in males lends further support for
future studies on the role of hormones in ion transport regulation
in BrS.
FUTURE DIRECTIONS
Future studies should aim to better understand the genetics
of BrS so as to enable researchers to create models that
represent the approximately 70% of patients who do not harbor
a SCN5A mutation. It is important also to investigate how
hormone regulation could lead to a seemingly greater prevalence
in men, how hormone regulation affects ion signaling, and
how gender influences cellular processes during changes in
temperature, heart rate, and vagal tone. Studies are warranted
to understand why and how the AS originates at the RVOT in
BrS, including expression levels of ion transport proteins and
the post-translational modification state of those proteins. It
would also be interesting to further understand the mechanism of
ajmaline, for example, if ajmaline administration alters the post-
translational modification status of key ion transport, contractile,
or gap junction proteins, particularly the same proteins affected
by the β-adrenergic response.
Donor hearts or animal models could be used to investigate
intracellular sodium, potassium, and calcium signaling, as well as
MCS and SR calcium store. Also, changes in post-translational
modification status and expression level of key regulatory
proteins could be studied, such as phosphorylation levels of
proteins in the β-adrenergic signaling pathway and SERCA and
phospholamban expression levels.
Another attractive tool for studying the pathogenic
mechanisms of BrS could be the use of induced-Cardiomyocytes
(iCMs), which have been recently derived from induced-
Pluripotent Stem Cells (iPSCs), or through the direct
reprogramming of fibroblasts. Indeed, a few groups have already
generated and used iCMs to perform electrophysiological
studies at the cellular level to characterize BrS ion current
alterations. In particular, iCMs obtained from fibroblasts from
BrS patients carrying an SCN5A mutation exhibited BrS
features, including a reduction in inward sodium current,
a shift in voltage-dependence curves and abnormal calcium
handling (Liang et al., 2016; Selga et al., 2018). Remarkably,
iCMs generated from BrS patients without SCN5A mutations
showed no significant functional difference when compared
to iCMs generated from healthy controls (Miller et al., 2017;
Koivumaki et al., 2018). These results highlight the limitations
of these studies, as clearly the BrS phenotype is observed
clinically in patients who test negative for SCN5A mutations.
Indeed, while iCMs possess most of the features of adult
cardiomyocytes, they still show an important functional and
electrical immaturity, accompanied also by morphological and
structural characteristics typical of embryonic cardiomyocytes.
This aspect still represents a major issue for iCMs use as
an in vitro model of adult cardiomyocytes, especially when
considering that ion channels are greatly modified during
embryogenesis and development (RIF).
CONCLUSION
Many questions remain to understand the clinical presentation
of BrS. Further human genomic studies are warranted to
better understand the commonalities between BrS patients.
Additional animal and cellular models are required to clarify the
questions outlined in this review, and much effort is needed to
improve their consistency and reproducibility before they can be
considered as effective tools to study BrS.
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